Pfizer reported earnings today, including good news for Sandoz and partner Momenta. Pfizer says the FDA this month upgraded the compliance status on a fill-finish plant in Kansas, lifting the hold that has kept Sandoz and Momenta from getting FDA
read moreAs the hemophilia market gets increasingly crowded, Roche needs all the help it can get generating enthusiasm for its new entry, Hemlibra. A thumbs-up from the cost watchdogs at the Institute for Clinical and Economic Review (ICER)—who decided Hemlibra is
read moreWhen Donald Trump said last year that pharma was “getting away with murder” and pledged to lower prices as president, biopharma shares plummeted. But Monday, Trump made a similar promise—that HHS Secretary Alex Azar would bring prices “way down”—and the
read moreRoche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market. More: Breakthrough status for Roche’s
read moreAstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD). More: AZ’ triple combo COPD inhaler hits PhIII targets Source:
read moreThe University of Cambridge is launching a new, £42-million research institute, tasked with gathering evidence to better support decisions on improving NHS care and organisation. More: Cambridge Uni launches £42m NHS care research institute Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals